Zanubrutinib Active Not Recruiting Phase 1 Trials for Malignant Lymphomas / Leukemias Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT02795182Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies